Other OTC - Delayed Quote USD

Ampio Pharmaceuticals, Inc. (AMPE)

0.2200 0.0000 (0.00%)
At close: May 15 at 3:38 PM EDT
Loading Chart for AMPE
DELL
  • Previous Close 0.2200
  • Open 0.2300
  • Bid --
  • Ask --
  • Day's Range 0.2200 - 0.2300
  • 52 Week Range 0.1350 - 8.2980
  • Volume 8,976
  • Avg. Volume 56,284
  • Market Cap (intraday) 249,779
  • Beta (5Y Monthly) 2.13
  • PE Ratio (TTM) --
  • EPS (TTM) -10.6600
  • Earnings Date Aug 6, 2024 - Aug 12, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. The company develops OA-201, a small molecule formulation for the treatment of OAK pain. Ampio Pharmaceuticals, Inc. is based in Englewood, Colorado.

ampiopharma.com

6

Full Time Employees

December 31

Fiscal Year Ends

Recent News: AMPE

Performance Overview: AMPE

Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

AMPE
89.27%
S&P 500
11.29%

1-Year Return

AMPE
95.22%
S&P 500
28.71%

3-Year Return

AMPE
99.96%
S&P 500
27.18%

5-Year Return

AMPE
99.85%
S&P 500
87.28%

Compare To: AMPE

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: AMPE

Valuation Measures

Annual
As of 5/14/2024
  • Market Cap

    249.78k

  • Enterprise Value

    -3.57M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    0.07

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -61.57%

  • Return on Equity (ttm)

    -113.96%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -8.63M

  • Diluted EPS (ttm)

    -10.6600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    4.12M

  • Total Debt/Equity (mrq)

    13.42%

  • Levered Free Cash Flow (ttm)

    -5.37M

Research Analysis: AMPE

Company Insights: AMPE

Research Reports: AMPE

People Also Watch